Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

143
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
143
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

68
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
68

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The methyl-CpG-binding protein 2 inhibits cGAS-associated signaling.

Nature communications·2025
Same author

Development of trofinetide for the treatment of Rett syndrome: from bench to bedside.

Frontiers in pharmacology·2024
Same author

Rett syndrome in Ireland: a demographic study.

Orphanet journal of rare diseases·2024
Same author

Sex representation in neurodegenerative and psychiatric disorders' preclinical and clinical studies.

Neurobiology of disease·2023
Same author

Editorial: Insights in cellular neurophysiology: 2021.

Frontiers in cellular neuroscience·2022
Same author

Editorial: Biology of brain disorders-Cellular substrates for disrupted synaptic function and experience-dependent plasticity.

Frontiers in cellular neuroscience·2022

Related Experiment Video

Updated: Jun 10, 2025

Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators
09:51

Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators

Published on: March 21, 2018

19.6K

Trofinetide treatment for Rett syndrome: Lessons to learn.

Daniela Tropea1

  • 1Department of Psychiatry, Trinity College Dublin, School of Medicine, Trinity Translational Medicine Institute, Trinity Center for Health Sciences, St James Hospital, D08W9RT Dublin, Ireland; Trinity College Institute of Neuroscience, Trinity College Dublin, Lloyd Building, Dublin 2, Ireland; FutureNeuro, The SFI Research Centre for Chronic and Rare Neurological Diseases, Dublin, Ireland.

Med (New York, N.Y.)
|October 12, 2024
PubMed
Summary

The FDA approved trofinetide, the first drug for Rett syndrome symptoms. LILAC trials show its long-term safety and effectiveness, offering hope for future treatments.

More Related Videos

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome
06:57

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome

Published on: September 13, 2020

2.9K
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.1K

Related Experiment Videos

Last Updated: Jun 10, 2025

Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators
09:51

Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators

Published on: March 21, 2018

19.6K
Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome
06:57

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome

Published on: September 13, 2020

2.9K
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.1K

Area of Science:

  • Neurology
  • Pharmacology
  • Rare Diseases

Background:

  • Rett syndrome is a rare neurodevelopmental disorder affecting girls.
  • There is a significant unmet need for effective treatments for Rett syndrome.
  • Trofinetide represents a novel therapeutic approach.

Purpose of the Study:

  • To evaluate the long-term safety and efficacy of trofinetide in individuals with Rett syndrome.
  • To assess the impact of trofinetide on Rett syndrome symptomatology.

Main Methods:

  • The LILAC trials investigated trofinetide's safety and efficacy.
  • Data from long-term treatment periods were analyzed.

Main Results:

  • Trofinetide demonstrated long-term safety in clinical trials.
  • Trofinetide showed efficacy in improving Rett syndrome symptoms.
  • The US FDA approved trofinetide, marking a significant milestone.

Conclusions:

  • Trofinetide is the first pharmacological treatment approved for Rett syndrome.
  • Insights from trofinetide trials can guide future research and treatment strategies for Rett syndrome and related disorders.